Clopidogrel BMS
Withdrawn
This medicine's authorisation has been withdrawn
clopidogrel
MedicineHumanWithdrawn
Latvian is available via eTranslation, the European Commission's machine translation service.
Translate to Latvian | Important information about machine translation
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
On 16 July 2008 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Clopidogrel BMS, clopidogrel, which had been approved for the prevention of atherothrombotic events in:
- Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
- Patients suffering from acute coronary syndrome: Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
The marketing authorisation holder (MAH) responsible for Clopidogrel BMS was Bristol Myers Squibb Pharma EEIG. The European Commission was notified by letter dated 20 October 2009 of the MAH’s decision to voluntarily withdraw the marketing authorisation for Clopidogrel BMS for commercial reasons.
On 12 November 2009 the European Commission issued a decision to withdraw the marketing authorisation for Clopidogrel BMS. Pursuant to this decision the European Public Assessment Report for Clopidogrel BMS is updated to reflect that the marketing authorisation is no longer valid.
Product information
Latest procedure affecting product information:N/0012
26/10/2009
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Clopidogrel BMS
- Active substance
- clopidogrel (as hydrogen sulfate)
- International non-proprietary name (INN) or common name
- clopidogrel
- Therapeutic area (MeSH)
- Stroke
- Peripheral Vascular Diseases
- Myocardial Infarction
- Acute Coronary Syndrome
- Anatomical therapeutic chemical (ATC) code
- B01AC04
Pharmacotherapeutic group
Antithrombotic agentsTherapeutic indication
Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:
- Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
- Patients suffering from acute coronary syndrome:
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
This page was last updated on